Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Antiandrogens in the Treatment of Prostatic Cancer

Antiandrogens in the Treatment of Prostatic Cancer Since prostatic carcinoma is hormone dependent, treatment of this tumor has been carriedout in this department over the last 10 years employing antiandrogens, particularly cyproterone acetate(CPA), associated in some cases with orchiectomy. Of 500 patients thus treated, the author reports on236 patients with a 5-year follow-up and 184 with a 7-year follow-up. Of these, 126 (53.4%) had notreceived hormone treatment whereas 110 (46.6%) had been treated with estrogens. The mean survivalrate was 64.4% at 5 years and 56.3% at 7 years in these patients and 51 and 43%, respectively, in theestrogen-treated patients. The author emphasizes that not only is CPA of great value in the treatment ofprostatic carcinoma, but it is also useful in determining the hormone dependency of the tumor which isindispensable before proceeding with hormone therapy. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Urology Karger

Antiandrogens in the Treatment of Prostatic Cancer

European Urology , Volume 5 (5): 4 – Jan 1, 2017

Loading next page...
 
/lp/karger/antiandrogens-in-the-treatment-of-prostatic-cancer-bf4c65oxkb

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 1979 S. Karger AG, Basel
ISSN
0302-2838
eISSN
1873-7560
DOI
10.1159/000473139
Publisher site
See Article on Publisher Site

Abstract

Since prostatic carcinoma is hormone dependent, treatment of this tumor has been carriedout in this department over the last 10 years employing antiandrogens, particularly cyproterone acetate(CPA), associated in some cases with orchiectomy. Of 500 patients thus treated, the author reports on236 patients with a 5-year follow-up and 184 with a 7-year follow-up. Of these, 126 (53.4%) had notreceived hormone treatment whereas 110 (46.6%) had been treated with estrogens. The mean survivalrate was 64.4% at 5 years and 56.3% at 7 years in these patients and 51 and 43%, respectively, in theestrogen-treated patients. The author emphasizes that not only is CPA of great value in the treatment ofprostatic carcinoma, but it is also useful in determining the hormone dependency of the tumor which isindispensable before proceeding with hormone therapy.

Journal

European UrologyKarger

Published: Jan 1, 2017

Keywords: Antiandrogens; Prostatic cancer; Cyproterone acetate

There are no references for this article.